Anticancer Activity of Pyrazole via Different Biological Mechanisms

Abstract

In the past few years pyrazole derivatives have attracted increasing attention because of their numerous potential pharmacological applications. Changes in their structure have offered a high degree of diversity that has proven useful for the development of new medicinal agents with improved potency and less toxicity. This review focuses on the recent developments in pyrazole along with their structure–activity relationship (SAR), particularly for anticancer activity. The review covers SAR for active pyrazole molecules such as cyclin dependent kinase (CDK) inhibitor (modulator), aurora kinase inhibitors (modulator), break point cluster region-Abelson (BCR-ABL) tyrosine kinase inhibitors (modulator), heat shock protein (HSP 90) inhibitors (modulator), polo-like kinase inhibitors (modulator), cyclo-oxygenase (COX) and lypo-oxygenase (LOX) inhibitors (modulator), epithelial growth factor receptor (EGFR) inhibitors (modulator), reticular activating system–neuro endocrine tumor (Ras-Net) ETS-like transcription factor (Elk-3) pathway inhibitors (modulator), and DNA binding agent.

GRAPHICAL ABSTRACT

Keywords:

• Enantiomers
• imatinib-resistant mutations
• lipoxygenases
• promyelecytic
• resorcinylic
• rofecoxib

View correction statement:

Corrigendum